MicroPort Scientific's (HKG:0853) subsidiary Shanghai MicroPort Endovascular MedTech (Group) (SHE:688016) expects to book net profit attributable to equity owners between 492.5 million yuan and 541.0 million yuan for 2024, 0.01% to 9.86% higher than the preceding year, a Monday Hong Kong bourse filing said.
The expected increase was attributed to an increase in overseas revenue and the number of Hospitals entered by Shanghai MicroPort Endovascular MedTech, a continued momentum contributed by its products, and an increase in the number of terminal implants for its new products during the reporting period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。